Drug Startups Eye Quicker Profits Under China’s New Fast-Track Approvals
Key changes designed to bring cutting-edge drugs more quickly to market have yet to ignite significant rally for money-losing startups Key takeaways: New fast-track approval system could bring cutting-edge drugs…
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
